This clinical trial is focused on studying the effects of a new treatment for atopic dermatitis, a condition that causes the skin to become red, itchy, and inflamed. The treatment being tested is called SCD-044, which is taken in the form of tablets. The active ingredient in these tablets is vibozilimod, a type of medication known as a selective immunosuppressive agent. This means it works by selectively reducing the activity of the immune system, which can help decrease inflammation and other symptoms associated with atopic dermatitis.

The purpose of the study is to determine how effective and safe SCD-044 is in treating moderate to severe cases of atopic dermatitis. Participants in the study will be randomly assigned to receive either the SCD-044 tablets or a placebo, which looks like the real medication but does not contain the active ingredient. The study will last for a period of 32 weeks, during which participants will take the tablets orally. The main goal is to see if there is at least a 75% improvement in the severity of the eczema, as measured by a specific index, by the end of the study period.

Throughout the study, participants will be monitored to assess any changes in their condition and to ensure their safety. The study aims to provide valuable information on whether SCD-044 can be an effective treatment option for those suffering from moderate to severe atopic dermatitis. This research could potentially lead to new ways to manage this challenging skin condition.